

University of California, San Francisco

DocuSigned by:  
  
 5D13E8EC33974C7...

**CURRICULUM VITAE**

**Name:** Thomas G Martin III, M.D.

**Position:** HS Clinical Professor, Step 4  
 Medicine  
 School of Medicine

**Address:** Hematology/Oncology Clinic 4th Floor Box 0324  
 400 Parnassus Ave, UC Clinics, A453  
 University of California, San Francisco  
 San Francisco, CA 94143  
 Voice: 353-9365  
 Fax: 353-2467  
 Email: tom.martin@ucsf.edu

**EDUCATION**

1982 - 1985	Cornell University, Ithaca, NY	BA	Genetics
1985 - 1989	University of Connecticut School of Medicine, Farmington, CT	MD	
1989 - 1990	Harbor-UCLA Medical Center, Torrance, CA	Internship	Internal Medicine
1990 - 1992	Harbor-UCLA Medical Center, Torrance, CA	Residency	Internal Medicine
1993 - 1996	UCSF Medical Center, San Francisco, CA.	Fellowship	Hematology/Oncology

**LICENSES, CERTIFICATION**

1991	Medical Licensure, California (G70576)
1999	Medical Licensure, Texas
1997	American Board of Medical Oncology, Board Certification
1992	American Board of Internal Medicine, Board Certification
1996	American Board of Hematology, Board Certification

**PRINCIPAL POSITIONS HELD**

1992 - 1993	Fagan ER Medical Group, Burbank, CA.	Associate Physician	
1992 - 1993	Kaiser Permanente, Bellflower, CA.	Courtesy Staff	Internal Medicine
1992 - 1993	Veterans Administration Medical Center, Long Beach, CA.	Attending Physician	Emergency Department

1993 - 1996	Kaiser Permanente, San Francisco, CA.	Courtesy Staff	Internal Medicine
1993 - 1997	California Pacific Medical Center, San Francisco, CA.	Staff Physician	Hematology/Oncology
1993 - 1998	University of California, San Francisco, CA.	Assistant Adjunct Professor	Hematology/Oncology
1999 - 2001	MD Anderson Cancer Center, Houston, TX	Assistant Professor of Medicine, Chief, Inpatient BMT Unit, Director, BMT Fellowship Program, Division of Blood and Marrow Transplantation	Medicine
2001 - present	University of California, San Francisco, CA	Director, Matched Unrelated Donor Program, Adult Leukemia and Bone Marrow Transplantation	Hematology/Oncology
2001 - 2003	University of California, San Francisco, CA	Assistant Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program	Hematology/Oncology
2003 - 2008	University of California, San Francisco, CA	Associate Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program	Hematology/Oncology
2004 - present	University of California, San Francisco, CA.	Co-Director, Multiple Myeloma Translation Initiative	Hematology/Oncology

2006 - 2012	University of California, San Francisco, CA.	Member, Committee on Human Research (CHR)	
2007 - 2015	University of California, San Francisco, CA.	Clinical Director, 11 Long Adult Stem Cell Transplantation	Hematology/Oncology
2009 - present	University of California, San Francisco, CA	Clinical Professor of Medicine, Adult Leukemia and Bone Marrow Transplantation Program	Hematology/Oncology
2017 - present	University of California, San Francisco, CA	Co-Leader Hematologic Malignancies Program, Helen Diller Family Comprehensive Cancer Center	Hematology/Oncology
2018 - present	University of California, San Francisco, CA	Interim Chief	Hematology/Oncology
2018 - present	University of California, San Francisco, CA	Director, Blood and Marrow Transplantation	Hematology/Oncology

**OTHER POSITIONS HELD CONCURRENTLY**

2011 - present	UCSF Medical Center	Research Director, Medicine Hematologic Malignancies Research Office	
2019 - present	UCSF Medical Center	Member, UCSF Institutional Review Board (IRB)	UCSF

**HONORS AND AWARDS**

1981	Valedictorian, Windsor High School, Windsor, CT.
1981	Dean's List Honors - Cornell University, University of Connecticut

- 1984 Cornell Tradition Fellow Award
- 1989 LANGE Book Award for Scholarship in Internal Medicine, University of Connecticut, Farmington, CT
- 2003 Faculty Teaching Award, Division of Hematology/Oncology, University of California, San Francisco, CA
- 2013 Center of the Year, Multiple Myeloma Research Consortium
- 2014 Nominated, Master Clinician, UCSF Medical Center

### **KEYWORDS/AREAS OF INTEREST**

My research interests include investigating novel therapeutics for the treatment of multiple myeloma. This includes developing and implementing early phase trials involving novel drugs and combinations, and developing novel immunotherapies including monoclonal antibodies, and cellular therapies. I am a member of the International Myeloma Foundation and Co-Lead the Immunotherapy Committee, which is an internationally recognized program. UCSF is also a member institution of the Multiple Myeloma Research Consortium and I have invested significant time to these collaborations. Overall, we have garnered an international reputation for our work in developing novel immunotherapies and thus have better access to novel drugs and this has increased patient referrals. In addition, preliminary studies involving novel immunotherapies including bispecific T-cell engaging antibodies and chimeric antigen receptor (CAR) T-cells, performed at UCSF, have shown significant preliminary efficacy in relapsed myeloma. This has been one of my main goals, to further develop our portfolio of immunotherapy trials at UCSF. This drives patient referrals enhances the careers of my myeloma faculty. I have been dedicated to mentoring Nina Shah, MD, Sandy Wong, MD, and now Alfred Chung, MD, and continue to try to enhance their careers and development as Myeloma researchers. They all participate in international and ground-breaking trials as UCSF Principal Investigators. I meet with them weekly to provide mentoring and support. I am also on the Steering Committee for several companies developing immunotherapies including Legend Biotech and GSK. Legend Biotech just licensed their Chimeric Antigen Receptor (CAR) T-cell therapeutic to Janssen and they have several other products in development that I will be able to get additional Lymphoma faculty at UCSF involved. I have worked on Isatuximab, a CD38 directed monoclonal antibody from Sanofi-Oncology, and helped this drug gain FDA approval. We recently published our results from a Phase 1 investigator initiated trial utilizing a novel combination of isatuximab with carfilzomib and this blossomed into a Phase III trial and will lead to FDA approval of this combination.

### **CLINICAL ACTIVITIES**

#### **CLINICAL ACTIVITIES SUMMARY**

Over the past ten years we have significantly increased our multiple myeloma referrals and now have one of the largest MM practices in the US. This has occurred through outreach to local physicians, through allowing access to novel clinical trials and through our interactions with myeloma support groups (IMF and MMRF). Our practice has grown substantially and we

perform increasing numbers of stem cell transplants and research cellular therapies for myeloma. Although I have taken on the roles of Interim Chief of Hematology and Director of the Blood and Marrow Transplantation program, I remain very active clinically. I attend on the inpatient service for 6-8 weeks per year and maintain 3 outpatient clinic sessions each week. I have 4 active clinical trials on-going and receive direct patient referrals as a result of these trials.

**CLINICAL SERVICES**

- 2001 - present Attending, Inpatient Service Adult Leukemia and Blood and Marrow Transplantation 6-8 weeks/year
- 2011 - present Attending, Outpatient Ambulatory Care Clinic and Infusion Center 6-8 weeks/year
- 2001 - present Attending, Continuing Care Clinic, Adult Hematology ACC 1.5 full days clinic/wk

**PROFESSIONAL ACTIVITIES**

**MEMBERSHIPS**

- 1995 - present American Society of Hematology
- 1997 - 2007 American Academy for the Advancement of Science
- 2000 - present American Society for Blood and Marrow Transplantation
- 2008 - 2012 Member, Committee on Human Research (CHR) Member, Clinical Research Office UCSF Cancer Center
- 2008 - 2019 Co-Chair, Hematology/Oncology P+T Subcommittee
- 2008 - 2013 Member, CIDP Credentialing Committee
- 2013 - present American Society of Clinical Oncology
- 2016 - present Society of Hematologic Oncology (SOHO)
- 2011 - present Member, International Myeloma Foundation
- 2009 - present Member, Multiple Myeloma Research Foundation
- 2019 - present Co-Chair, Immunotherapy Committee, International Myeloma Foundation

**SERVICE TO PROFESSIONAL ORGANIZATIONS**

- 2014 - 2017 American Society of Clinical Oncology Plasma cell disorder committee
- 2014 - present National Comprehensive Cancer Network (NCCN) Panel Member, Multiple Myeloma
- 2016 - present Society of Hematologic Oncology (SOHO) Education Committee member

2020 - present	Myeloma Program Chair, SOHO 2021 Meeting	Myeloma Chair
2014 - present	International Myeloma Foundation	Instructor, Chinese Physicians Class

**SERVICE TO PROFESSIONAL PUBLICATIONS**

2013 - present	Journal Review, Editorial Board, AACR, ad hoc reviewer BLOOD and Clinical Leukemia, Lymphoma, Myeloma
----------------	-------------------------------------------------------------------------------------------------------

**INVITED PRESENTATIONS - INTERNATIONAL**

2014	Hematology Symposium April 2014: Advances in Myeloma, Tel Aviv, Israel	Lecturer
2015	International Myeloma Foundation, Rome, Italy: Topic - Antibody therapy in Relapsed and Refractory Myeloma	Lecturer
2016	3rd Annual Summit on Hematologic Malignancies, Whistler, Canada: Topic - Genetic Factors Associated with Response to Therapy fro hematologic Malignancies	Lecturer
2017	International Myeloma Foundation, New Dehli, India: Topic - Toxicities from Immunotherapies in Multiple Myeloma	Lecturer
2018	Asian Myeloma Society - International Myeloma Foundation 3rd Annual Symposium, Beijing, China	Lecturer
2019	Asian Myeloma Society - International Myeloma Foundation 4th Annual Symposium, Bangkok, Thailand	Lecturer
2020	6th World Congresses on Controversies in Multiple Myeloma (COMy), Paris France	Lecturer

**INVITED PRESENTATIONS - NATIONAL**

1996	Presidential Plenary Session: Annual Meetings of the AGA and AASLD, San Francisco, CA, May 1996. Topic: Thrombopoietin May Play a Major Role in the Thrombocytopenia in Cirrhosis.	Lecturer
1996	Grand Rounds: Department of Laboratory Medicine, UCSF Medical Center, August 1996. Topic: Thrombocytopenia in Health and Disease.; Intramural Meetings	Lecturer
1996	Grand Rounds: Department of Medicine, Division of Gastroenterology, UCSF Medical Center, December 1996. Topic: Thrombocytopenia in Cirrhosis.; Intramural Meetings	Lecturer
1998	Hemostasis and Thrombosis Seminar: Department of Medicine, Division of Hematology and Oncology, UCSF Medical Center, March 1998. Topic: New Thrombopoietic Agents-Preclinical and Clinical Studies.; Intramural Meetings	Lecturer

2000	International Symposium: XXIV Hematology Congress of Brasil; Rio de Janeiro, Brasil May 2000. Topic: Prevention and Management of Chemotherapy-Induced Thrombocytopenia, Invited Lectures	Lecturer
2000	American Society of Hematology: Symposium; San Francisco, CA December 2000. New Horizons for Acute Myelogenous Leukemia Patients with Limited Treatment Options: Topic: Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia, Invited Lectures	Lecturer
2001	German Leukemia Society: International Symposium; Munich, Germany, February 2001. Topic: Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous leukemia, Invited Lectures	Lecturer
2001	Whistler Oncology Seminar: New Developments in Oncology; Whistler, Canada, February 2001. Topic: New Treatments for Acute Myelogenous Leukemia, Invited Lectures	Lecturer
2001	American Society of Blood and Marrow Transplantation: Pharmacy Symposium, Keystone, CO, March 2001. Topic: Non-Myeloablative Transplantation for the Treatment of Hematopoietic Malignancies, Invited Lectures	Lecturer
2001	City of Hope Seminar: Rational Therapeutics: A Seminar in General Medicine; Anaheim, CA, June 2001. Topic: Utilization of Monoclonal Antibodies in Oncology, Invited Lectures	Lecturer
2000	International Oncology Network: Seminar: ASH Updates: Scottsdale, AZ, April 2002. Topic: New Treatments for Acute Myelogenous Leukemia, Invited Lectures	Lecturer
2002	Grand Rounds: Veterans Administration Hospital, Westwood, CA 2002. Topic: Targeted therapy for Relapse Acute Myelogenous Leukemia , Invited Lectures	Lecturer
2001	Silverado Oncology Conference, Napa CA 2003. Topic: New Therapies for Treating Fungal Infections in the Immunocompromised Host, Invited Lectures	Lecturer
2000	California Blood Bank Society, Berkeley, CA 2004. Topic: Advances in Stem Cell Transplantation, Invited Lectures	Lecturer
2000	Association of Northern California Oncologists, Berkeley, CA 2005. Topic: ASH Updates in Myeloma and Myelodysplasia, Invited Lectures	Lecturer

2001	Leukemia and Lymphoma Society Patient Advocacy Group, CA 2005. Topic: Advances in Myeloma, Invited Lectures	Lecturer
2002	ASH Review: Advances in Myeloma Treatment; San Francisco, CA 2007., Invited Lectures	Lecturer
2003	ASH Update: Advances in Supportive Care for Stem Cell Transplantation; San Francisco, CA, Invited Lectures	Lecturer
2008	Leukemia and Lymphoma Society; Patient Advocacy Group, Oakland, CA Advances in Myeloma, Invited Lectures	Lecturer
2008	Grand Rounds: San Francisco, VA Medical Center: Advances in Myeloma, Invited Lectures	Lecturer
2009	UCSF Clinical Cancer Update at Squaw Valley, CA: Advances in Myeloma, Invited Lectures	Lecturer
2010	UCSF Helen Diller Comprehensive Cancer Center Symposium: Clinical Developments in Multiple Myeloma	Lecturer
2011	Treatment of Relapse Myeloma: CME Lecture. Seattle, Washington.	Lecturer
2012	Multiple Myeloma Research Consortium: Patient Seminars; multiple events - San Francisco, CA; Scottsdale, AZ; Westwood, CA.	Lecturer
2014	Meet the Professor; April 2014: Hadassah University, Jerusalem, Israel	Lecturer
2013	American Society of Hematology, Oral Presentation: Phase I Dose Escalation Trail of Single Agent SAR650984 in Relapsed Myeloma	Lecturer
2014	American Society of Clinical Oncology, Oral Presentation: Phase I Dose Escalation Trail of SAR650984 in Combination with Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma	Lecturer
2014	American Society of Hematology 56th Annual Meeting, Oral Presentation: Personalizing Multiple Myeloma Treatment for Maximum Benefit	Lecturer
2015	Association of Northern California Oncologists (ANCO): Hematologic Malignancies Update: Update in Myeloma	Lecturer
2015	American Society of Hematology 57th Annual Meeting, Oral Presentation: A Dose Finding Phase II Trial of Isatuximab (Anti-CD38 mAb) as a Single Agent in Relapsed and Refractory Multiple Myeloma	Lecturer



2015	American Society of Hematology 57th Annual Meeting, Oral Presentation: Immunotherapy for the Treatment of Multiple Myeloma	Lecturer
2016	Annual Oncology Symposium: Swedish Medical Center, Seattle Washington. Oral Presentation: Frontline Therapy for Multiple Myeloma	Lecturer
2016	Society of Hematologic Oncology (SOHO): Houston, TX. Current Frontline Therapy for Multiple Myeloma	Lecturer
2017	American Society of Clinical Oncology, Oral Presentation: Primary Refractory Myeloma	Lecturer
2017	Society of Hematologic Oncology: Houston, TX. Immunotherapy in Myeloma - Clues to Use of Monoclonal Antibodies	Lecturer
2018	4th Annual Symposium for Immuno-Oncology in Multiple Myeloma, San Francisco, CA - Novel Antibody Therapy	Lecturer
2018	Society of Hematologic Oncology: Houston TX. Novel therapies for Relapsed Myeloma	Lecturer
2019	International Myeloma Working Group, Annual Meeting, Boston, MA: CD38, Next Generation Therapies	Lecturer
2019	American Society of Hematology: Friday Symposium: Orlando, FLA; Immunotherapy for Relapsed Myeloma	Lecturer
2020	American Society of Clinical Oncology: Annual Meeting: Chicago, IL; Harnessing Immunotherapy: Bispecific Antibodies: a "2 for 1"	Lecturer
2020	American Society of Hematology: Friday Symposium: Virtual ASH: Immunotherapy Advances in Myeloma	Lecturer
2020	American Society of Hematology: International, randomized, IKEMA Phase 3 Clinical Trial Results	Presenter

### **GOVERNMENT AND OTHER PROFESSIONAL SERVICE**

2014 - present	National Comprehensive Cancer Network (NCCN)	Panel Member
----------------	----------------------------------------------	--------------

### **UNIVERSITY AND PUBLIC SERVICE**

#### **SERVICE ACTIVITIES SUMMARY**

I have continued to work with the Multiple Myeloma Research Foundation at multiple events from 2013-2020; during 5 events I functioned as a speaker for a patient education seminar (2 at UCSF, 1 Atlanta, GA; 1 NY, NY; and 1 in Scottsdale AZ) and I volunteered as the master of ceremonies for the annual MMRF walk on Marina Green yearly since April 2014-2019.

I have also volunteered for the International Myeloma Foundation and served as a speaker for multiple educational symposia in Redwood City and Century City, CA and the latest one being virtual with >600 participants (2016-2020)

I have volunteered to give a lectures to the Bay Area Multiple Myeloma Patient Support Group since 2014.

**UCSF CAMPUSWIDE**

2008 - 2012 CIDP Credentialing Committee Member

**SCHOOL OF MEDICINE**

2008 - 2012 Committee on Human Research Member

2019 - present Committee on Human Research Member

**SCHOOL OF PHARMACY**

2010 - 2017 P+T Oncology Sub-Committee Member

**DEPARTMENTAL SERVICE**

2010 - present Hematologic Malignancies Research Program Director

2004 - 2018 Matched Unrelated Donor Selection Committee Director

2017 - present Helen Diller Family Comprehensive Cancer Center, Hematologic Malignancies Program Co-Lead

**TEACHING AND MENTORING**

**TEACHING SUMMARY**

Teaching has always been one my priorities and there are many venues to help foster education at UCSF. I was given the Teaching Award for our division as selected by the fellows back in 2003. I enjoy teaching fellows during inpatient rounds and in the outpatient setting. From 2008-2015, I was responsible for developing the teaching program associated with the 11 Long Fellowship rotation. Fellows received two didactic sessions each week and designated teaching sessions at the microscope. I enjoy having teaching rounds during clinic and during the day-to-day rounds on 11 Long. I have been a Small Group teacher for the Medical School since 2010. This is for the first and second year medical students. This has been a great experience and I have received positive feedback from the students. This continues to be a important role for me.

**FORMAL TEACHING**

	Academic Yr	Course No. & Title	Teaching Contribution	School	Class Size
	2011 - 2020	Intro to Cancer: Hematology Block	Small Group Leader	Medicine	15

**INFORMAL TEACHING**

2005 - present Teaching on 11 Long Rounds: 6-8 hours/week (total 60-90 hours/year)

2004 - present Teaching in the Outpatient Clinic: 1.5-2 hours each week (60-80 hours)

**MENTORING SUMMARY**

I have enjoyed mentoring residents, fellows and junior faculty. I was nominated for the DOM Mentoring award in 2020. I have mentored many fellows who have been interested in MM and AML and they have gone on to become faculty and leaders at other programs. I currently meet with my junior faculty weekly and this is my favorite part of my week. Watching these young physicians develop into the next generation of leaders is fun to watch and an important part of my career.

**POSTDOCTORAL FELLOWS AND RESIDENTS MENTORED**

Dates	Name	Fellow	Mentor Role	Faculty Role	Current Position
2009 - 2011	Ajai Chari, MD	Oncology	Research/Scholarly Mentor, Career Mentor, Co- Mentor/Clinical Mentor	Mentor	Associate Professor, Mount Sinai Hospital, NY, NY
2013 - 2014	Gabriel Mannis, MD	Oncology	Research/Scholarly Mentor, Career Mentor, Co- Mentor/Clinical Mentor	Mentor	Associate Professor, Stanford University, CA
2013 - 2015	Daniel Sherbenou, MD PhD	Oncology	Career Mentor, Co- Mentor/Clinical Mentor	Clinical Mentor	Assistant Professor in Residence, University of Colorado, Denver, CO
2016 - 2017	Derek Galligan, MD	Oncology	Co- Mentor/Clinical Mentor	Clinical Mentor	Assistant Professor, VA, Portland, OR
2019 - 2020	August Dietrich, MD	Oncology	Co- Mentor/Clinical Mentor	Clinical Mentor	Fellow
2018 - 2020	Guy Ledergor, MD	Medicine Resident	Career Mentor, Co- Mentor/Clinical Mentor	Mentor	UCSF Intern

**FACULTY MENTORING**

Dates	Name	Position while Mentored	Mentor Type	Mentoring Role	Current Position
2016 - 2017	Sandy Wong, MD	Assistant Clinical Professor	Career Mentor	Mentor	Assistant Professor
2016 - 2019	Nina Shah, MD	Associate Clinical Professor	Career Mentor	Mentor	Professor as of 2020
2020 - present	Alfred Chung, MD	Assistant Professor	Career Mentor	Mentor	Assistant Professor
2014 - 2018	Gabriel Mannis, MD	Assistant Professor	Career Mentor, Co-Mentor/Clinical Mentor	Mentor	Associate Professor at Stanford

**RESEARCH AND CREATIVE ACTIVITIES****RESEARCH AND CREATIVE ACTIVITIES SUMMARY**

My research interests include novel therapies for multiple myeloma and acute myelogenous leukemia. I am currently working together with Sanofi-Aventis on developing their novel anti-CD38 monoclonal antibody (SAR650984) in the treatment of multiple myeloma. I am the national Principal Investigator for 3 Phase I/II multicenter studies. I am on the Steering Committee for a Phase III licensing trial. The results of this trial have recently been accepted by Lancet and I am the senior author. I have given numerous oral presentations at National meetings regarding this compound. SAR650984 is one of the most exciting novel agents in the treatment of myeloma and we have treated more patients at UCSF than any other center in the world. We also have performed some pre-clinical murine xenograft tumor models testing SAR650984 in combination with other therapies and we have the only Investigator Initiated Trial (IIT) for this compound. The results of the UCSF IIT have just been accepted for publication by the journal Cancer.

Through the Multiple Myeloma Translational Initiative (MMTI) at UCSF we have performed pre-clinical studies on a novel anti-CD46 antibody drug conjugate. This anti-CD46 ADC, developed by Bin Liu, PhD at UCSF, is one of the most active compounds we have tested. The drug is being developed by the investment company Fortis, and we are leading the first-in-man Phase I study at UCSF. I have designated Sandy Wong, MD as UCSF PI and will continue to mentor her through this project. This is a unique example drug development at UCSF from bench to bedside. We are the leading center for enrollment and have seen clinical responses.

I have an interest in novel antibody therapy and will be UCSF PI on an industry Phase I clinical trial using two novel bispecific T-cell engaging antibodies and this has already been activated and we have seen excellent responses. Our experience with bispecifics has been very promising and we are working with several philanthropic sources to begin developing novel bispecifics at UCSF.

The development and use of cellular therapies for treatment of relapsed and refractory myeloma has generated significant excitement. I have been able to attract 6 early phase clinical trials (4 CAR-T cell trials and 2 NY-ESO1 targeted TCR trials) to UCSF, and we have contributed greatly to national accrual to these studies. I have designated Nina Shah and Sandy Wong as UCSF PI for the first 3 studies. I have also been asked to be on the Steering Committee for Legend Biotech, a company from China that wants to test other novel CAR T-cells in the USA. I have been an investigator on an industry study using Legend's CAR T-cell product at UCSF. This study has been taken over by Janssen, and we have completed accrual and the results have been submitted to Lancet - for which I will be an author. All these studies and opportunities have garnered national recognition for the UCSF Myeloma Program. I now Co-Chair the Immunotherapy Committee for the International Myeloma Foundation and Co-Chair the Immunology Section for the Asian Myeloma Network.

I have initiated a collaboration between the Myeloma Program at Emory University and UCSF. Together we will develop and investigate a novel "homegrown" BCMA targeted CAR T-cell project using a vector obtained from Lentigen, Inc. Multiple other projects will develop out of this collaboration - both science and clinical, and this will be very important for our Myeloma Program and for the younger investigators.

We are investing philanthropic funds into generating novel CAR T-cell vectors for the treatment of relapsed MM. We have initiated a collaboration between the Marson, Eyquem and Wiita laboratories at UCSF and hope to compete for NIH funding for this project.

### RESEARCH AWARDS - CURRENT

1.	Principal Investigator		Martin (PI)
	Sanofi S.A.	12/12/2014	12/11/2021
	A Phase Ib Study of SAR650984 (Anti-CD38mAb) in combination with Carfilzomib for the Treatment of Relapsed or refractory Multiple Myeloma		
	To determine adverse events, maximum tolerated immunogenicity of SAR650984, overall response rate, clinical benefit response, overall survival, progression free survival, time to progression and duration of response.		
2.	Principal Investigator	2 % effort	Martin (PI)
	Sanofi Aventis and Onyx Pharmaceuticals	10/31/2014	12/31/2025
	Phase I Study of SAR650984 in combination with Carfilzomib and dexamethasone for relapse and refractory multiple myeloma: direct/yr 1	\$ 500,000	\$ 3,500,000 total
	Additional Dosing ARM added		
	This is an ongoing study with 1 new cohort starting to enroll		
	Study PI. Wrote the protocol, enrolled the patients, evaluated the data, submitted manuscript. Designed the additional cohort		
3.	MMRC-066 Washington University Co-Principal Investigator		Martin (PI)
	The Multiple Myeloma Research Foundation	04/08/2016	12/31/2025

A Phase II Study of IRD (Ixazomib, Lenalidomide, and Dexamthasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma (A127214)

To determine the improvement in MRD-negative rate after 4 cycles of IRD consolidation

4. IMF Award	Principal Investigator		Martin (PI)
International Myeloma Foundation		04/24/2018	05/17/2023
Redefining natural history of Smoldering Multiple Myeloma and developing a new risk stratification system (A131141)			
5. EFC15246	Principal Investigator		Martin (PI)
Sanofi US		08/08/2018	08/08/2023
Randomized, open label, multicenter study assessing the clinical benefit of isatuximab combined with carfilzomib ((Kyprolis) and dexamethasone versus carfilzomib with dexamethason in patients with relapsed and/or refractory multiple myeloma. (A131761)			
6. 20160445	Principal Investigator		Martin (PI)
Amgen, Inc.		06/06/2019	06/06/2024
A Phase 1, First-in-Human, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 424 in Subjects with Multiple Myeloma. (A133312)			
7. 68284528MMY2001	UCSF Principal Investigator	2 % effort	Martin (PI)
68284528MMY2001		08/06/2019	08/24/2024
A Phase 1b-2, Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Relapsed or Refractory Multiple Myeloma. (A133540)		\$ 550,000 direct/yr 1	\$ 700,000 total
This is a Phase 2 CAR T-cell trial			
8 patients enrolled at UCSF			

**RESEARCH AWARDS - SUBMITTED**

1. 64007957MMY1001	Principal Investigator	1 % effort	Martin (PI)
Janssen Pharmaceuticals, Inc		10/08/2019	10/08/2024
A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, A Humanized BCMA x CD3 Bispecific Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma.		\$ TBD direct/yr 1	\$ TBD total
I will be site Principal Investigator			
Enroll patients			

**RESEARCH AWARDS - PAST**

1.	Principal Investigator		Martin (PI)
Sanofi Aventis		03/01/2013	12/31/2018
Phase I Study of SAR650984 in Combination with Lenalidomide and Dexamethasone for Relapse and Refractory Multiple Myeloma		\$ 125, 000 direct/yr 1	\$ 500,000 total

Enroll patients, evaluate data, overall PI of study

2.	Principal Investigator		Martin (PI)
Alliance Cooperative Group		07/15/2013	12/31/2019
BMT CTN0702: Randomized trial of Autologous transplantation using single vs. tandem vs. single plus consolidation therapy in patients with newly diagnosed multiple myeloma		\$ 15, 000 direct/yr 1	\$ 25,000 total

Enroll patients, evaluate data

**PEER REVIEWED PUBLICATIONS**

1. Malchoff CD, Javier EC, Malchoff DM, Martin TG, et al: Primary Cortisol Resistance Presenting as Isosexual Precocity. *Journal of Endocrinology and Metabolism*. 70:2, 503-9, 1990.
2. Meng, YG, Martin TG, Peterson ML, Shuman M, Cohen RL, Wong W: Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. *British Journal of Haematology*. 95: 535-541, 1996
3. Meng YG, Martin TG, Peterson ML, Shuman MA, Cohen RL, Wong WL. Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. *Br J Haematol*. 1996 Dec; 95(3):535-41. PMID: 8943898
4. Martin TG, Somberg K, Cohen RL, Shuman MA, Meng YG: Thrombopoietin levels in cirrhotic patients before and after orthotopic liver transplantation. *Annals of Internal Medicine*. 127:4, 285-288, 1997.

5. Martin TG, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, Shuman MA. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. *Ann Intern Med.* 1997 Aug 15; 127(4):285-8. PMID: 9265428
6. Martin, TG and Shuman, M.A; Interferon-Induced Thrombocytopenia: Is It Time for Thrombopoietin? *Hepatology.* 28:5, 1430-1432, 1998.
7. Martin TG, Shuman MA. Interferon-induced thrombocytopenia: is it time for thrombopoietin. *Hepatology.* 1998 Nov; 28(5):1430-2. PMID: 9794932
8. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin, RE, Korbling M; A comparative study of once-daily versus twice daily filgrastim administration for the mobilization and collection of CD34(+) peripheral blood progenitor cells in normal donors. *British Journal of Hematology.* 109, 770-772, 2000.
9. Anderlini P, Donato M, Lauppe MJ, Huh YO, Martin TG, Chan KW, Champlin RE, Körbling M. A comparative study of once-daily versus twice-daily filgrastim administration for the mobilization and collection of CD34+ peripheral blood progenitor cells in normal donors. *Br J Haematol.* 2000 Jun; 109(4):770-2. PMID: 10929027
10. Martin, TG and Gajewski JA: Allogeneic Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia. *Hematology/Oncology Clinics of North America.* 15:1 97-120, 2001.
11. Shimoni A, Gajewski JA, Donato M, Martin T, O'Brien S, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. *Biol Blood Marrow Transplant.* 2001; 7(10):568-75. PMID: 11760089
12. Martin, TG and Linker, CA: Autologous Stem Cell Transplantation for Adults with Acute Lymphoblastic Leukemia. *Hematology/Oncology Clinics of North America.* 15:1 21- 143, 2001
13. Martin TG, Linker CA. Autologous stem cell transplantation for acute lymphocytic leukemia in adults. *Hematol Oncol Clin North Am.* 2001 Feb; 15(1):121-43. PMID: 11253604
14. Shimoni A, Gajewski J, Donato M, Martin TG, O'Brien S, Huh V, Talpaz M, Cohen A, Korbling M, Champlin R, Giralt S: Long-Term Follow-up of Recipients of CD8-depleted Donor Lymphocyte Infusions for the Treatment of Chronic Myelogenous Leukemia Relapsing After Allogeneic Progenitor Cell Transplantation. *Biology of Blood and Marrow Transplantation.* 7:568-575, 2001
15. Martin TG, Gajewski JL. Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults. *Hematol Oncol Clin North Am.* 2001 Feb; 15(1):97-120. PMID: 11253611
16. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Korbling M, Martin TG, Ueno NT, Champlin RE, Khouri IF: Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. *Annals of Oncology.* 13:450-459, 2002
17. Hosing C, Munsell M, Yazji S, Andersson B, Couriel D, de Lima M, Donato M, Gajewski J, Giralt S, Körbling M, Martin T, Ueno NT, Champlin RE, Khouri IF. Risk of therapy-related



myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma. *Ann Oncol*. 2002 Mar; 13(3):450-9. PMID: 11996478

18. Thall PF, Inoue LYT and Martin TG: Adaptive Decision Making in a Lymphocyte Infusion Trial. *Biometrics*. 58:560-568, 2002
19. Thall PF, Inoue LY, Martin TG. Adaptive decision making in a lymphocyte infusion trial. *Biometrics*. 2002 Sep; 58(3):560-8. PMID: 12229990
20. Martin TG, Giralt S, Khouri I, Champlin RE: Non-Myeloablative Stem Cell Transplantation for Acute Myelogenous Leukemia. *Acute Leukemias IX. Hematology and Blood Transfusion*. 41:483-484, 2003
21. Wong R, Giralt SA, Martin T, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. *Blood*. 2003 Oct 15; 102(8):3052-9. PMID: 12842990
22. Gunn N, Damon L, Varosy P, Navarro W, Martin TG, Reis C, Linker C. High CD34 Cell Dose Promotes Faster Platelet Recovery After Autologous Stem Cell Transplantation for Acute Myeloid Leukemia. *Biol Blood Marrow Transplant*, 10:643-8, 2003
23. Gunn N, Damon L, Varosy P, Navarro W, Martin T, Ries C, Linker C. High CD34+ cell dose promotes faster platelet recovery after autologous stem cell transplantation for acute myeloid leukemia. *Biol Blood Marrow Transplant*. 2003 Oct; 9(10):643-8. PMID: 14569560
24. Wong R, Giralt SA, Martin TG, Couriel DR, Anagnostopoulos A, Hosing C, Andersson BS, Cano P, Shahjahan M, Ippoliti C, Estey EH, McMannis J, Gajewski JL, Champlin RE, de Lima M: Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. *Blood*. 102(8):3052-9, 2003
25. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. *Leukemia*. 2003 Dec; 17(12):2538-40. PMID: 14523458
26. Khorshid O, de Meis E, Martin TG, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M: Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. *Leukemia*. 17(12):2538-40, 2003
27. Couriel DR, Saliba R, Hicks K, Ippoliti C, De Lima MJ, Hosing C, Khouri I, Andersson B, Donato M, Gajewski J, Anderlini P, Kontoyiannis DP, Cohen A, Martin TG, Giralt S, Champlin R: Tumor necrosis factor alpha blockade for the treatment of steroid-refractory acute GVHD. *Blood* 2004 Aug 1;104(3):649-54.
28. Couriel D, Saliba R, Hicks K, Ippoliti C, de Lima M, Hosing C, Khouri I, Andersson B, Gajewski J, Donato M, Anderlini P, Kontoyiannis DP, Cohen A, Martin T, Giralt S, Champlin R. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. *Blood*. 2004 Aug 1; 104(3):649-54. PMID: 15069017
29. Damon L, Rugo H, Tolaney S, Navarro W, Martin TG, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor

- cells with high doses of cyclophosphamide and etoposide plus filgrastim. *Biol Blood Marrow Transplant.* 2006 Mar;12(3):316-24.
30. Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim. *Biol Blood Marrow Transplant.* 2006 Mar; 12(3):316-24. PMID: 16503501
  31. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin TG, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. *Bone Marrow Transplant.* 2006 Sep;38(6):421-6.
  32. Lekakis L, Giralt S, Couriel D, Shpall EJ, Hosing C, Khouri IF, Anderlini P, Korbling M, Martin T, Champlin RE, de Lima M. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies. *Bone Marrow Transplant.* 2006 Sep; 38(6):421-6. PMID: 16892072
  33. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. *Leukemia.* 2008 Feb;22(2):258-64.
  34. de Lima M, Champlin RE, Thall PF, Wang X, Martin TG, Cook JD, McCormick G, Qazilbash M, Kebriaei P, Couriel D, Shpall EJ, Khouri I, Anderlini P, Hosing C, Chan KW, Andersson BS, Patah PA, Caldera Z, Jabbour E, Giralt S. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome. *Leukemia.* 2008 Feb; 22(2):258-64. PMID: 17989720
  35. Damon L, Damon LE, Gaensler K, Kaplan L, Martin TG, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. *Bone Marrow Transplant.* 2008 Nov; 42(10):649-57.
  36. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T, Rubenstein J, Linker C. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. *Bone Marrow Transplant.* 2008 Nov; 42(10):649-57. PMID: 18679366. PMCID: PMC4372391
  37. Martin TG, Sharma M, Damon L, Kaplan L, Guglielmo BJ, Working M, O'Malley R and Linker C. Voriconazole is Safe and Effective as Prophylaxis for Early and Late Fungal Infections Following Allogeneic Hematopoietic Stem Cell Transplantation. *Transpl Infect Dis.* 2010 Feb; 12(1):45-50.
  38. **Martin TG** and Wolf J. Bortezomib: Safety and Efficacy in the Treatment of Multiple Myeloma. *Clinical Medicine Reviews in Oncology.* 2010 Nov; 10:4137.
  39. Paul G. Richardson, Jeff Wolf, Andrzej Jakubowiak, Jeff Zonder, Sagar Lonial, David Irwin, John Densmore, Amrita Krishnan, Noopur Raje, Michael Bar, **Tom Martin**, Robert Schlossman, Irene M. Ghobrial, Nikhil Munshi, Jacob Laubach, Jeff Allerton, Teru Hideshima, Kathleen Colson, Enrique Poradosu, Lesa Gardner, Peter Sportelli, Kenneth C. Anderson. Perifosine Plus Bortezomib and Dexamethasone Extends Progression-Free

Survival and Overall Survival in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase I/II Trial: *J Clin Onc*: 2011 Nov 10; 29(32):4243-9.

40. Linker C, Damon L, Martin T, Blume K, Forman S, Snyder D, Wolf J, Negrin R. Autologous hematopoietic cell transplantation for high-risk ALL. *Bone Marrow Transplant*. 2011 Mar; 46(3):460-1. PMID: 20531287
41. McCarthy P, Hofmeister C, Hurd D, Hassoun H, Richardson P, Giralt S, Stadmauer E, Weisdorf D, Vij R, Moreb J, Callander N, van Besein K, Gentile T, Isola L, Maziarz R, Gabriel T, Bashey A, Landau H, **Martin TG**, Qazilbash M, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelley M, Seiler M, Rosenbaum C, Hari P, Pasquini M, Horowitz M, Shea T, Devine S, Anderson K, and Linker C. A phase III randomized, double-blind study of maintenance therapy with lenalidomide or placebo following autologous hematopoietic cell transplantation for multiple myeloma: for the Cancer and Leukemia Group B / Eastern Cooperative Oncology Group / Blood and Marrow Transplant Clinical Trials Network. *N Engl J Med*. 2012 May 10;366(19):1770
42. Siegel DS, **Martin TG**, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. *Blood*. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.
43. Wang M, **Martin TG**, Bensinger W, Alsina M, Siegel D, Kavalierchik E, Huang M, Orlowski RZ, Niesvizky R. Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Blood*. 2013 Oct 31; 122(18):3122-8.
44. Niesvizky R, Martin TG, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M. Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Clin Cancer Res*. 2013 Apr 15; 19(8):2248-56. PMID: 23447001. PMCID: PMC4149337
45. Siegel D, **Martin TG**, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S. *Hematologica*. 2013 Nov; 98 (11): 1753-61.
46. Martin TG. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib. *Oncology (Williston Park)*. 2013 Dec; 27 Suppl 3:4-10. PMID: 25184230
47. Badros AZ, Vij R, **Martin TG**, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. *Leukemia*. 2013 Jan 31. doi: 10.1038/leu.2013.29.
48. Jakubowiak AJ, Siegel DS, **Martin TG**, Wang M, Vij, R, Lonial S, Trudel, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadmauer E, Harrison B, Wong A, Orlowski RZ, Jagannath S. Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agents carfilizomib in the PX-171-003-A1 study. *Leukemia*. 2013 Dec; 27(12): 2351-6.

49. Niesvizky R, **Martin TG**, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orłowski RZ, Wang M. Phase 1b dose-escalation study (PX-171-006) of carfilzomib, lenalidomide and low-dose dexamethasone in relapsed or progressive multiple myeloma. *Clin Cancer Res.* 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.CCR-12-3352. Epub 2013 Feb 27.
50. Mannis G.N., Logan A.C., Leavitt A.D., Yanada M., Hwang J., Olin R.L., Damon L.E., Andreadis C., Ai W.Z., Gaensler K.M., Greene C.C., Gupta N.K., Kaplan L.D., Mahindra A., Miyazaki Y., Naoe T., Ohtake S., Sayre P.H., Smith C.C., Venstrom J.M., Wolf J.L., Caballero L., Emi N., **Martin T.G.** Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. *Bone Marrow Transplant* 2014; 10.1038.
51. Keller JW, Andreadis C, Damon LE, Kaplan LD, Martin TG, Wolf JL, Ai WZ, Venstrom JM, Smith CC, Gaensler KM, Hwang J, Olin RL. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients. *J Geriatr Oncol.* 2014 Jul; 5(3):238-44. PMID: 24894413
52. Vij R, Mazumder A, Klinger M, O'Dea D, Paasch J, **Martin TG**, Weng L, Park J, Fiala M, Faham M, Wolf J. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients. *Clin Lymphoma Myeloma Leuk.* 2014 Apr 14(2): 131-139
53. Mannis G, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai W, Gaensler K, Kaplan L, Koplowitz Y, Linker C, Olin R, Sayre P, Smith C, Sudhinda A, Venstrom JM, Wolf J, **Martin TG.** Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia, *Clin Lymph Myeloma.* Submitted 9/2014
54. Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE, Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD, Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM, Wolf JL, Caballero L, Emi N, Martin TG. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. *Bone Marrow Transplant.* 2015 Jan; 50(1):40-4. PMID: 25243620
55. Sherbenou DW, Behrens CR, Su Y, Wolf JL, Martin TG, Liu B. The development of potential antibody-based therapies for myeloma. *Blood Rev.* 2015 Mar; 29(2):81-91. PMID: 25294123
56. Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamrozik K, Jurczynski A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patient. *Nat Commun.* 2015 Jul 22:6:7539.
57. Baz RC, Martin TG 3rd, Lin HY, Zhao X, Shain KH, Cho HJ, Wolf JL, Mahindra A, Chari A, Sullivan DM, Nardelli LA, Lau K, Alsina M, Jagannath S. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. *Blood* 2016 May 26:127(21):2561-8.
58. Mannis GN, Martin TG 3rd, Damon LE, Logan AC, Olin RL, Flanders MD, Ai WZ, Gaensler KM, Kaplan LD, Sayre PH, Smith CC, Wolf JL, Andreadis A. Long-term outcomes of

patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission. *Leuk Lymphoma* 2016 Jul; 57(7):1560.

59. Mannis GN, Martin TG 3rd, Damon LE, Andreadis C, Olin RL, Kong KA, Faham M, Hwang J, Ai WZ, Gaensler KM, Sayre PH, Wolf JL, Logan AC. Quantification of acute lymphoblastic leukemia clonotypes in leukapheresed peripheral blood progenitor cells predicts relapse risk after autologous hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant* 2016 Jun;22(6):1030
60. Mule MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Multigene measurable residual disease assessment improves acute myeloid leukemia relapse risk stratification in autologous hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2016 Nov;22(11):1974.
61. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. *J Clin Invest* 2016 Dec 1;126(12):4640.
62. Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Sheath DA, Kumar R. Multiple myeloma: version 3.2017. NCCN clinical practice guidelines in oncology. *J Natl Compr Canc Netw*. 2017 Feb;15(2):230.
63. A Vogl DT, Martin TG, Vij R, Hari P, Mikheal JR, Seigel D, Wu KL, Delforge M, Gasparetto C. Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma. *Leuk Lymphoma* 2017 Aug;58(8):1872.
64. Le Moigne R, Aftab B, Djakovic S, Dhimolea E, Valle E, Murnane M, King EM, Soriano F, Menon MK, Wu ZY, Wong ST, Lee GJ, Yao B, Wiita AP, Lam C, Rice J, Wang J, Chesi M, Bergsagel PL, Kraus M, Driessen C, Kiss von Soly S, Yakes FM, Wustrow D, Shawver L, Zhou HJ, Martin TG, Wolf JL, Mitsiades CS, Anderson DJ, Rolfe M. The P97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of multiple myeloma. *Mol Cancer Ther* 2017 Sep;6 (Epub 2017)
65. Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giral S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bahey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after autologous stem-cell transplantation for multiple myeloma: a randomized, double-blind, phase 3 trial. *Lancet Haematol* 2017 Sep;4(9) (Epub 2017)
66. Martin TG, Baz R, Benson D, Lendvai N, Wolf J, Munster P, Leshokhin AM, Wack C, Charpentier E, Campana F, Vij R. A Phase Ib study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. *Blood* 2017. Aug; 58(8):1872-1879. PMID: 30862646
67. Kumar SK, Callander NS, Alsina M, Atanackovic D, Bierman JS, Castillo J, Chandler JC, Costello C, Faiman M, Fung HC, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kang Y, Kassim A, Liedtke M, Malek E, Martin TG, Neppalli VT, Omel J, Raje N,

- Singhal S, Somlo G, Stockerl-Goldstein K, Weber D, Yahalom J, Kumar R, Shea DA. NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. *J Natl Compr Canc Netw*. 2018 Jan;16(1):11-20.
68. Tan M, Kalin-Hajdu E, Narayan R, Wong SW, Martin TG. Zoledronic acid-induced orbital inflammation in a patient with multiple myeloma. *J Oncol Pharm Fract*. 2018 Jan 1:1078155218785967. Doi: 10.1177/1078155218785967. [Epub ahead of print] PubMed PMID: 30005587.
69. Leleu X, Martin TG, Einsele H, Lyons RM, Durie BGM, Iskander KS, Ailawadhi S. Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma. *Clin Lymphoma Myeloma Leuk* 2019 Jan;19(1)9-22. Doi: 10.1016/j.clml.2018.08.016 Epub 2018 Sep 5. Review. PMID 30287200
70. Kaufman JL, Mina R, Jakubowiak AJ, Zimmerman TL, Wolf JJ, Lewis C, Gleason C, Sharp C, Martin TG, Heffner LT, Nooka AK, Harvey RD, Lonial S. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: Results of a Multiple Myeloma Research Consortium Phase I Study. *Blood Cancer J*. 2019 Jan 4:9(1):3. doi: 10.1038/s41408-018-0154-8. PubMed PMID: 30610196; PMCID: PMC6320362.
71. Nawas MT, Andreadis C, Martin TG, Wolf JL, Ai WZ, Kaplan LD, Mannig GN, Logan AC, Damon LE, Huang CY, Olin RL. Limitation in Patient-Reported Function Is Associated with Inferior Survival in Older Adults Undergoing Autologous Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Jan 30.pii S1083-8791(19)30086-2. doi: 10.1016/j.bbmt.2019.01.028. [Epub ahead of print] PubMed PMID: 3070189.
72. Martin TG, Strickland S, Glenn M, Charpentier E, Guillermin H, Hsu K, Mikhael J. Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma. *Blood Cancer J*. 2019 Mar 29;9(4):41. doi: 10.1038/s41408-019-0198-4. PubMed PMID: 30926770; PubMed Central PMCID: PMC6440961
73. Mikhael J, Ismaila N, Cheung MC, Costello C, Dhodapkar MV, Kumar S, Lacy M, Lipe B, Little RF, Nikonova A, Omel J, Peswani N, Prica A, Raje N, Seth R, Vesole DH, Walker I, Whitley A, Wildes TM, Wong SW, Martin TG. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline. *J Clin Oncol*. 2019 Apr 1: JCO1802096. doi: 10.1200/JCO.18.02096. [Epub ahead of print] PubMed PMID:30932732.
74. Mikhael J, Ismaila N, Martin TG. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Summary. *J Oncol Pract*. 2019 Apr 1:JOP1800782. Doi: 10.1200/JOP.18.00782. [Epub ahead of print] PubMed PMID: 30933544.
75. Martin T and Huff CA. Current Advances and Future Directions. *Clin Lymphoma Myeloma Leuk*. 2019 May;19(5):255-263. doi: 10.1016/j.clml.2019.03.025. Epub 2019 Apr 1.
76. Kumar SK, Callander NS, Hillengass J, Liedtke M, Baljevic M, Campagnaro E, Castillo JJ, Chandler JC, Cornell RF, Costello C, Efebera Y, Faiman M, Garfall A, Godby K, Holmberg L, Htut M, Huff CA, Kang Y, Landgren O, Malek E, Martin T, Omel J, Raje N, Sborov D, Singhal S, Stockerl-Goldstein K, Tan C, Weber D, Johnson-Chilla A, Keller J, Kumar R, NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020. *J Natl Compr Canc Netw*. 2019 Oct 1;17(10):1154-1165.
77. Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC. Therapeutic opportunities with pharmacological inhibition of CD38 with isatuximab. *Cells*. 2019 Nov 26;8(12):1522. doi:10.3090/cells8121522

78. Moreau P, Dimopoulos MA, Yong K, Mikhael J, Risse ML, Asset G, Martin T. Isatuximab plus carfilzomib/dexamethasone versus carfilzomib dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design. *Future Oncol* 2020. Jan;16(2): 4347-4358;doi: 10.2217/fo-2019-0431. Epub 2019 Dec 13.
79. Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, Bensinger W, Dimopoulos M, Lendvai N, Hari P, Ocio EM, Gasparetto C, Kumar S, Oprea C, Chiron M, Brillac C, Charpentier E, San-Miguel J, Martin T. A dose-finding phase II study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. *Leukemia*. 2020 May 14. doi: 10.1038/s41375-020-0857-2.
80. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann B, Wolf JL, Martin TG, Liu B. Potent activity of an anti-ICAM1 antibody-drug conjugate against multiple myeloma. *Clin Cancer Res*. 2020 Sep 11:clincanres.0400.2020. doi: 10.1158/1078-0432.CCR-20-0400
81. Kambhampati S, Galligan D, Huang CY, Wong S, Wolf J, Martin T, Shah N. A single-center retrospective cohort analysis of venetoclax in relapsed/refractory multiple myeloma. *Leuk Lymphoma*. 2020 May;61(5):1211-1219. doi: 10.1080/10428194.2019.1709835.
82. Alonso R, Cedena MT, Wong S, Shah N, Ríos-Tamayo R, Moraleda JM, López-Jiménez J, García C, Bahri N, Valeri A, Sánchez R, Collado-Yurrita L, Martin T, Wolf J, Lahuerta JJ, Martínez-López J. Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma. *Blood Adv*. 2020 May 26;4(10):2163-2171. doi: 10.1182/bloodadvances.2020001508. PMID: 32433744

## SIGNIFICANT PUBLICATIONS

1. Mannis G, Andreadis C, Logan AC, Damon LE, Benet LZ, Ai W, Gaensler K, Kaplan L, Koplowicz Y, Linker C, Olin R, Sayre P, Smith C, Sudhindra A, Venstrom JM, Wolf J, **Martin TG**. Phase I Study of Targeted, Dose-Escalated Intravenous Busulfan in Combination with Etoposide as Myeloablative Therapy for Autologous Stem Cell Transplantation in Acute Myeloid Leukemia, *Clin Luek Lymph Myeloma*. Submitted 9/2014

I designed and wrote the study, performed the research, and did the data analysis. I helped Dr Mannis write the final paper and it was recently submitted for publication.

2. Mannis G.N., Logan A.C., Leavitt A.D., Yanada M., Hwang J., Olin R.L., Damon L.E., Andreadis C., Ai W.Z., Gaensler K.M., Greene C.C., Gupta N.K., Kaplan L.D., Mahindra A., Miyazaki Y., Naoe T., Ohtake S., Sayre P.H., Smith C.C., Venstrom J.M., Wolf J.L., Caballero L., Emi N., **Martin T.G**. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis. *Bone Marrow Transplant* 2014; 10.1038.

I discovered the clinical problem, performed the data collection, and helped Dr Mannis with the data analysis. I helped Dr Mannis write the final paper.

3. **Martin TG**, Baz R, Benson D, Lendvai N, Campana F, Charpentier E, Vij R. A Phase Ib study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. *Blood*. 2017 Jun 22;129(25):3294.

I designed and wrote the clinical study. I selected all the multicenter sites. I enrolled the most patients across the country and helped perform the data analysis.

4. **Martin TG**, Strickland S, Glenn M, Wolf J, Hsu K, Charpentier E, Mikhael J. Phase I Trial of SAR650984 (Anti-CD-38 mAb) in the Treatment of Refractory Hematologic Malignancies Including Multiple Myeloma. *Blood Cancer J.* 2019 Mar 29;9(4):41. doi: 10.1038/s41408-019-0198-4. PubMed PMID: 30926770; PubMed Central PMCID: PMC6440961

I enrolled the most patient across the country in the clinical study. I re-wrote the paper and submitted it to Sanofi.

5. Martin TG, Baz R, Benson D, Lendvai N, Wolf J, Munster P, Leshokhin AM, Wack C,/> Charpentier E, Campana F, Vij r. A Phase Ib study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. *Blood* 2017. Aug; 58(8):1872-1879. PMID: 30862646

I led the study nationally, enrolled the most patient across the country and wrote the paper. Published in *Blood*.

6. Mikhael J, Ismaila N, Martin TG. Treatment of Multiple Myeloma: ASCO and CCO Joint Clinical Practice Guideline Summary. *J Oncol Pract.* 2019 Apr 1;JOP1800782. Doi: 10.1200/JOP.18.00782. [Epub ahead of print] PubMed PMID: 30933544.

I led the national effort for creating ASCO and CCO Joint Clinical Practice Guidelines for the treatment of MM. Published in *JCO*.

7. Martin T, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Seigel D, Biran N, Wolf J, Parekh S, Cho HJ, Munster P, Richard S, Campana F, Chari A. Phase 1b Trial of Isatuximab, an Anti-CD38 Monoclonal Antibody, in Combination with Carfilzomib as Treatment of Relapsed/ Refractory Multiple Myeloma. *Cancer*, accepted 12/2020

I wrote the study, led the national multi-center trial in collaboration with the MMRF, and submitted the manuscript. This study led to a Phase III trial which will allow FDA approval of this combination.

8. Moreau P, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu J,X, Oriol A, KohY, Suzuki K, Risse ML, Asset G, Mace S, Martin T. Isatuximab, carfilzomib and dexamethasone in relapsed multiple myeloma. *Lancet*, accepted Feb 2021.

Our Phase I study, led to the P3 international multi-center trial. I was on the study steering committee, enrolled patients and helped to author the manuscript. This will eventually lead to FDA approval of this combination.

## CONFERENCE ABSTRACTS

1. Molldrem JJ, Kant S, Lu S, Rios R, Streicher H, Wang C, Giral S, O'Brien S, Cortes J, Champlin RC, Martin TG, Wieder E: Peptide Vaccination with PR1 Elicits Active T Cell Immunity That Induces Cytogenetic Remission in Acute Myelogenous Leukemia. *Blood*, 93: 8 8a, 2002.
2. Lowe J, Lee P, Fei D, Meng YG, Wong WL, Cohen RL, Martin TG, Morgan DA, Koren E: Bioassay for TPO Activity in Human Serum Using Megakaryoblastic HU-3 Cell Line. *Blood*, 86:10, 3601a, 1997.



3. Martin TG, and Shuman MA: Transfusion Therapy during Liver Transplantation is Dependent on the Pre-transplantation Platelet Count. *Blood*, 90:10, 3316a, 1997.
4. Lebeurier I, Martin TG, and Shuman, MA: Primitive Megakaryocyte Progenitors are Enriched in Cord Blood compared with Chemotherapy and G-CSF Mobilized Peripheral Blood. *Blood*, 86:10, 3376a, 1997.
5. de Lima M, Komanduri K, St. John L, Wieder E, Lee M, McMannis J, Karandish S, Giralt S, Beran M, Couriel D, Korbling M, Martin TG, Andersson B, Bibawi S, Westmoreland M, Hosing C, and Champlin R. Using Two Mismatched Unrelated Donor Cord Blood Units For Transplantation: Analysis of Chimerism and Immune Reconstitution. *Blood*, 98:11, 5192a, 2001.
6. Martin TG, Shahjahan M, de Lima M, Couriel D, Champlin R, Gajewski J, Giles F, Kantarjian H, Andersson B and Giralt S. The Use of Mylotarg as Anti-leukemia Therapy Increases the Incidence of Liver Toxicity Including VOD Following Allogeneic Transplantation. *Blood*, 98:11, 803a, 2001
7. Anagnostopoulos A, de Lima M, Munsell M, Shahjahan M, Couriel D, Martin TG, Cano P, McMannis J, Gajewski J, Anderson B, Champlin R, Giralt S. Unrelated donor bone marrow transplantation (UDR) for adults with AML/MDS: similar outcomes with ablative or reduced intensity preparative regimens (RIPR). *Blood* 2002.
8. De Lima M, Wong R, Martin TG, Couriel D, Anagnostopoulos A, Shahjahan M, Hosing C, Andersson B, Donato M, Cano P, Ippoliti C, Estey E, Gajewski J, Champlin R, Giralt S. Unrelated Donor Hematopoietic Stem Cell Transplantation/> (HSCT) for the treatment of Myeloid Malignancies in Patients Older than 55 years of Age. *Blood* 2002.
9. Dhruva A, Damon L, Linker C, **Martin TG**, and Navarro W. A Retrospective Review of Outcomes of Patients with Chronic Myelomonocytic Leukemia Treated with 5-Azacitidine. *Blood*, Nov 2005; 106: 4931a.
10. Chari A, Kaplan L, Linker C, Damon L, Navarro W, and Martin TG. Phase I/II Study of Bortezomib in Combination with Liposomal Doxorubicin and Melphalan in Relapsed or Refractory Multiple Myeloma. *Blood*, Nov 2005; 106: 5182a.
11. Richardson P, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Allerton JP, Schlossman R, Ghobrial I, Munshi N, Martin TG, Laubach J, Colson K, Dean S, Tocco D, Steinfield E, Kendall T, O'Riley K, Hideshima T, Sportelli P, Gardner L, and Anderson K. Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib *Blood*, Nov 2008; 112: 870a.
12. **Martin TG**, Hong S, Damon L, Kaplan L, Navarro W, and Linker C. Tacrolimus, Mini-Methotrexate and Mycophenolate Mofetil is Safe and Effective as Acute GVHD Prophylaxis for Non-Myeloablative Unrelated Donor Allogeneic Transplantation. *Blood* Nov 2009
13. Percival ME, Damon LE, **Martin TG**, Kaplan L, Ai W, Wolf JL, Hong S, Linker C, Ries C and Andreadis C. Long-Term Outcomes in Patients with Acute Myelogenous Leukemia (AML) Following Allogeneic Stem Cell Transplantation (AlloSCT) for Relapse After Initial Autologous Bone Marrow Transplant (ASCT). *Blood* Nov 2009.

14. Giermasz A, MD, Damon E, Kaplan L, Navarro W, Hege, Linker C and **Martin TG**. Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy In Adults with Hematopoietic Disorders Undergoing Matched Unrelated Donor Stem Cell Transplantation. Blood Nov 2010
15. Siegel DS, Kaufman JL, Wang M, **Martin TG**, Jagannath S, Niesvizky R, Reu FJ, Alsina M, Badros A, Gabrail NY, Kukreti V, Singhal S, Le MH, Kotlovker D, Bomba D, Hannah AL, and Vij R. Carfilzomib in patients with relapsed and/or refractory multiple myeloma: summary of safety and efficacy data upon long-term treatment. International Myeloma Workshop 2011.Paris, France. May 3–6, 2011.
16. Jakubowiak A, **Martin TG**, Singhal S, Wang M, Vij R, Jagannath S, Lonial S, Kukreti V, Buadi F, Kunkel LA, Bray L, Vallone M, Wong AF, Orlowski RZ, Siegel DS, and The Multiple Myeloma Research Consortium (MMRC). Effects of cytogenetics on responses and survival in patients with relapsed and refractory multiple myeloma (R/R MM) treated with single-agent Carfilzomib. International Myeloma Workshop 2011.Paris, France. May 3–6, 2011.
17. Niesvizky R, Bensinger W, **Martin TG**, Alsina M, Siegel D, Gabrail N, Hari P, Singhal S, Vescio R, Assouline S, Kunkel L, Vallone M, Wong A, Wang M. An UPDATE on the Phase 1b/2 Dose-escalation Study of Carfilzomib with Lenalidomide and Low-dose Dexamethasone (CRd) in PATIENTS WITH Relapsed or Refractory Multiple Myeloma. Blood, November 2011.
18. **Martin TG**, Baz R, Benson D, Lendvai N, Campana F, Charpentier E, Vij R. A Phase Ib dose escalation trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma. Submitted ASH 2014
19. Siegel DS, Berdeja JG, Infante J, Kaufman J, Wang M, **Martin TG**, Niesvizky R, Reu FJ, Jagannath S, Rajangam K, Huang M, Vij R. Updated Results from a Phase 2 Extension Study of Patients with Multiple Myeloma or Solid Tumors Previously Enrolled in Carfilzomib Company-Sponsored Phase 1 and 2 Clinical Trials (PX-171-010). Submitted ASH 2014.
20. Rachid Baz, MD, **Thomas G. Martin III, M.D.**, Melissa Alsina, MD, Kenneth H. Shain, MD, PhD, Hearn J. Cho, MD, PhD, Jeffrey L Wolf, MD, Anuj Mahindra, M.D., Ajai Chari, MD, Daniel M Sullivan, MD, Lisa A Nardelli, BS, CCRP, Kenneth Lau, BA, Xiuhua Zhao, Hui-Yi Lin, PhD and Sundar Jagannath, MD: Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study (56th ASH Annual Meeting Abstracts), Abstract 303, December 2014.
21. John Marra, BS, Juan Du, MD, PhD, Jimmy Hwang, Ph.D., Jeffrey L Wolf, MD, **Thomas G. Martin III, M.D.** and Jeffrey M Venstrom, MD: KIR and HLA Genotypes Influence Clinical Outcome in Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in Combination with Lenalidomide and Dexamethasone (56th ASH Annual Meeting Abstracts), Abstract 2126, December 2014.
22. Blake T. Aftab, PhD, Daniel J Anderson, PhD, Ronan Le Moigne, PhD, Stevan Djakovic, PhD, Eugen Dhimolea, PhD, Megan Murnane, Emily King, Julie Rice, Steve Wong, Brajesh Kumar, PhD, Eduardo Valle, Mary-Kamala Menon, Szerenke Kiss von Soly, Jinhai

- Wang, PhD, Bing Yao, Ferdie Soriano, Martin Kampmann, PhD, Diego Alcost-Alvear, PhD, Marta Chesi, PhD, Leif Bergsagel, M.D., F. Michael Yakes, PhD, Han-Jie Zhou, PhD, David Wustrow, PhD, **Thomas G. Martin III, M.D.**, Jeffrey L. Wolf, M.D., Constantine S. Mitsiades, MD, PhD and Mark Rolfe, PhD: Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma (56th ASH Annual Meeting Abstracts), Abstract 4701, December 2014.
23. Thomas G. Martin III, M.D., Rachid Baz, MD, Don M. Benson Jr., MD, PhD, Nikoletta Lendvai, MD, PhD, Frank Campana, MD, Eric Charpentier and Ravi Vij, MBBS, MD: A Phase 1b Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (56th ASH Annual Meeting), Abstract 83, December 2014.
24. Martin T, Richter J, Vij R, Cole C, Atanackovic D, Zonder J, Kaufman J, Bensinger W, Dimopoulos M, San Miguel J, Zimmerman T, Lendvai N, Hari P, Ocio E, Gasparetto C, Kumar S, Hsu K, Charpentier E, Strickland S, Mikhael J. A Dose Finding Phase II Trial of Isatuximab (SAR650984, antiCD38 mAb) as a Single Agent in Relapsed/Refractory Multiple Myeloma. (57th ASH Annual Meeting), Abstract December, 2015; [Blood 126(23):509]
25. Vij, R, Lendvai N, Martin T, Baz R, Campana F, Mazuir F, Charpentier E, Benson D. A Phase 1b Trial of Isatuximab plus Laneliddomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Interim Results from 2 New Dose Cohorts. Abstract ASCO Annual Meeting, June 2016
26. Martin T, Mannis G, Chari A, Munster P, Campana F, Hui AM, Wolf J. Phase 1b Study of Isatuximab and Carfilzomib in Relapsed and Refractory Multiple Myeloma. (58th ASH Annual Meeting), Abstract December 2016 [Blood 128(22):2111]
27. Martin T, Dimopoulos M, Yong K, Mikhael J, Risse ML, Asset G, Moreau P. Phase 3 (IKEMA) study design: Isatuximab plus Cafilzomib and Dexamethasone (Kd) vs. Kd in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Abstract ASCO Annual Meeting June 2018
28. Vij R, Martin T, Nathwani N, Fiala M, Gao F, Deol A, Buadi F, Kaufman J, Hofmeister C, Gregory T, Berdeja J, Chari A, Rosko A. (59th ASH Annual Meeting), Abstract, December 2019 [Blood 134(suppl 1):602]

### **ACADEMIC LEADERSHIP**

I was appointed Interim Chair of the Division of Hematology in October 2018. This appointment was intended to be for ~1 year but with the Covid pandemic the job is ongoing. I have not otherwise changed my clinical or research work and thus have worked above and beyond. This has been a very challenging time to take on this leadership role - Covid, racial injustices, and growing pains in the program. Despite these challenges, I think the Division and specifically our Heme/BMT group is stronger than before and on a great trajectory for growth.

I have also taken on the leadership role of Director of Blood and Marrow Transplantation. We have steadily increased the number of transplants performed each year and have maintained FACT accreditation. I have also incorporated cellular therapies, specifically CAR T-cell therapy under the transplantation umbrella. This will be responsible for much growth over the next few years, thus much more to do. I am actively involved in planning expansion of our footprint/clinic/infusion center at 400 Parnassus and working with UCSF Health to optimize patient care, throughput and patient and staff satisfaction.

My interactions with DOM leadership and Cancer Center leadership have provided significant learning opportunities for me and has led improved job satisfaction. Overall, these roles have been challenging yet fun and I look forward to new challenges each day.

**ADDITIONAL RELEVANT INFORMATION**

**Teaching/Mentoring Experience:**

Director, Fellowship Program, MD Anderson Blood and Marrow Transplantation, Discussant, Journal Club 2000-2001

Core Leader, UCSF Hematology/Oncology Fellowship Education, 11 Long Didactic Series 2001-Present

Attending Bone Marrow Transplantation Service, UCSF Medical Center, Daily Rounds and Resident Lectures Bi-weekly 2001- Present

Instructor, Hematology Core Curriculum, UCSF Medical School 2001- Present